DrugCendR Announces Pancreatic Cancer Clinical Trial Data, New Member of Board of Directors and FDA Orphan Drug Designation
31 janv. 2019 03h31 HE
|
DrugCendR Inc.
LA JOLLA, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing next generation cancer therapies designed to overcome the...